The first interlocutory injunction restraining the launch of a biosimilar pharmaceutical product was granted by the Federal Court of Australia in a decision on 12 June 2018¹. Background The decision concerns the monoclonal antibody rituximab, a biologic therapy which is prescribed in Australia to treat a number of immunology conditions including lymphoma, chronic lymphocytic leukaemia …
>> Read more
A recent opposition decision of the Australian Patent Office¹ focused on the level of disclosure which is required in a patent specification to properly enable and support the claimed invention. This decision illustrates the importance of providing an enabling disclosure across the full width of the claimed invention and, where possible, providing a principle of …
>> Read more
In a recent post, we highlighted the grave risks of failing to disclose the ‘best method known to the applicant of performing the invention’, as required by section 40 of the Australian Patents Act. A question that was left open was whether such a failure might be remedied by filing a divisional application with the …
>> Read more
In the latter part of 2017, IP Australia sought comment on a proposed bill, the Intellectual Property Laws Amendment (Productivity Commission Response Part 1 and Other Measures) Bill (Part 1 Bill), for changes to a number of IP policy matters – one of which included the abolishment of Australia’s innovation patent system. The proposed change …
>> Read more
The NRG COSIA Carbon XPRIZE seeks to incentivise development of carbon capture and utilisation (CCU) technologies that convert carbon dioxide (CO2) into useful products while mitigating climate change. Ten finalists (carbon.xprize.org/teams) were selected to compete for a USD$20 million pot, by demonstrating their technologies at pilot scale using power station flue gas as the CO2 …
>> Read more
The Australian innovation patent system has been in the news recently as a result of the Australian Government’s intention to abolish the system. This decision followed the general inquiry made by the Productivity Commission into Australia’s intellectual property (IP) system. The expectation within the IP industry was that abolition of the innovation patent system would …
>> Read more
Today, new regulations come into effect which clarify the requirements for filing divisional patent applications in New Zealand. These regulations, the Patent Amendment Regulations 2018, allow a divisional application to be filed with claims that overlap in scope with the claims of the parent application (including, for example, refiling the same claim set as the …
>> Read more
Australia’s innovation patent system is championed by IP professionals and small to medium enterprises, but has been by under fire from the Productivity Commission for some time on the basis that the system was viewed as producing low value patents and created uncertainty for innovators in relation to infringement of other party’s patents. As a …
>> Read more
Businesses that purchase Australian patented goods are free to use them in any manner desired unless the patentee imposes conditions at the time of sale. However, does this still apply when the purchased goods are modified in the course of refurbishment and resold? This issue was recently considered by the Federal Court in the patent …
>> Read more
Syngenta Crop Protection AG v Bayer Intellectual Property GmbH [2018] APO 19 (9 March 2018) Syngenta has been successful in its opposition to two related Bayer patent applications. The patents relate to an insecticidal composition comprising a synergistically effective combination of one neonicotinoid compound selected from [a number of listed neonicotinoids] and an anthranilamide compound. …
>> Read more
